Parkinson's Disease is a new study from Decision Resources, Inc., that evaluates the most recent drug development and treatment strategies for Parkinson's disease (PD). Our research indicates that new trends in medical practice will yield commercial opportunities for drugs that delay the need for levodopa or that can be used as adjuncts to levodopa therapy. In this study, we identify market opportunities for current and emerging drugs to treat PD over a 2000-2010 forecast period.
The growing PD population, long disease duration, and the increased use of polytherapy with some of the newer, more-expensive agents will make PD a highly lucrative market for effective drugs. New therapies will include novel dopamine agonists, compounds targeting nondopaminergic systems (e.g., glutamate antagonists), and neurotrophic factor therapies that may offer neuroprotection and/or neurorestoration.
The continuing trend toward the use of levodopa-sparing strategies to treat patients with early-stage disease will result in a decrease in the percentage of PD patients taking dopamine precursors (i.e., levodopa preparations). However, the overall market value of the dopamine precursor drug class will increase because of the growing PD population and the introduction of novel levodopa preparations (e.g., levodopa pro-drugs) that will carry high price tags.
The delayed use of levodopa will also result in increased use of dopamine agonists. Ropinirole (GlaxoSmithKline's Requip) and pramipexole (Pharmacia's Mirapex) will remain the top-selling dopamine agonists in the United States through 2010, with ropinirole seeing a boost in sales upon the introduction of a once-daily, controlled-release formulation by 2005. Pergolide (Eli Lilly's Celance/Permax) will remain one of the most popular dopamine agonists in Europe and Japan, despite experiencing a modest decline in favor of newer agents. Novel dopamine agonists entering the market will face considerable competition and so will most likely target niche populations.
The increased use of combination therapies will be another major factor fueling growth in the PD market during our forecast period. The biggest contributors to growth in this sector will be novel glutamate antagonists, monoamine oxidase-B (MAO-B) inhibitors, and other novel therapies.
Parkinson's Disease offers invaluable market intelligence for pharmaceutical companies developing therapies to treat this disease. This study is a part of Cognos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553, or